Bicara Therapeutics Inc. (BCAX)
Nasdaq: BCAX · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2024
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | Mar 30, 2026 | Mar 27, 2025 | · |
| Research and development | · | 63,600 | 30,600 |
| General and administrative | 30,508 | 18,770 | 9,272 |
| Total operating expenses | 155,604 | 82,389 | 39,889 |
| Operating income | -155,604 | -82,389 | -39,889 |
| Interest and investment income | 17,871 | 14,581 | 1,314 |
| Total non-operating income (expense) | 17,871 | 14,581 | -12,091 |
| Income before income taxes | -137,733 | -67,808 | -51,980 |
| Income tax expense | 217 | 187r | 5 |
| Net income | -137,950 | -67,995 | -51,985 |
| Earnings per share, basic | -2.52 | -4.05 | -89.61 |
| Earnings per share, diluted | -2.52 | -4.05 | -89.61 |
| Weighted average shares, basic | 54,676,896,000 | 16,805,524,000 | 580,109,000 |
| Weighted average shares, diluted | 54,676,896b | 16,805,524b | 580,109b |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding